by Raynovich Rod | Apr 17, 2013 | Biopharmaceuticals, Macro
Major Sell-Off Early On April 17–Correction is Here with Some Technical Damage Posted 12.15p EDT, Update at 4:56p The rally yesterday was apparently a head fake as a major sell-off resumed today with the NASDAQ down 2.10% and the S&P down 1.7%. The gold free...
by Raynovich Rod | Apr 15, 2013 | 2025 Rayno Biopharmaceuticals Portfolio, BIOgraph, Clinical Diagnostics and Tools, Macro
Gold Crash Spooks Traders-Life Science Stocks Lose Resilience IBB ($166.82) Down 1.6% Rayno Life Science Stocks- Quick Look With NAZ at 2343 We have not made any Rayno Portfolio changes but have added two stocks recently: Genomic Health (GHDX) and Hologic (HOLX) both...
by Raynovich Rod | Apr 12, 2013 | 2025 Rayno Biopharmaceuticals Portfolio, Macro
Biotech and Drug Stocks Remain in the Sweet Spot NAZ Down 0.16% at 3295 at Close A string of market up days was halted today as retail sales and consumer sentiment gave bearish indicators.Commodity stocks were also weak-energy down 1.2%, materials down 1.7%- and there...
by Raynovich Rod | Apr 10, 2013 | Macro
Concern About FED Tightening Reverses Psychology And Becomes Another Reason To Buy Equities QE May End This Summer FED minutes were released early showing concern about exit from $4T inventory of bonds and further effects of QE like the current asset bubble, future...
by Raynovich Rod | Apr 4, 2013 | 2025 Rayno Biopharmaceuticals Portfolio, BIOgraph, Macro
Biotechnology Sector Q2 2013- At All Time Highs The BTK and ETFs such as the IBB and XBI hit all time highs on April 2. Of course the current ramp cannot go on forever because money moves on, speculation ebbs and math intervenes. We have been picking biotech stocks...
by Raynovich Rod | Apr 3, 2013 | BIOgraph, Macro
Pause in Rally as Large Cap Biotechs Are Weak There is significant weakness today in many high fliers that is not apparent in the S&P, NASDAQ and Russell averages. The IBB hit a new high yesterday at the $162 level and is off 1% today. Large Cap leaders YTD are...
by Raynovich Rod | Mar 14, 2013 | Biopharmaceuticals, Macro
Technicals Matter in a MOmentum Market Some important trends are developing in momentum stocks some of which are on in our Life Science Portfolio. As we have written previously many momentum stocks are being driven by media buzz, novel business models and sponsorship...
by Raynovich Rod | Mar 5, 2013 | 2025 Rayno Biopharmaceuticals Portfolio, Macro
FED Fuel Fans Feuer The monetized momentum market rolled on today despite the backdrop of bearish commentary from celebrity pundits and strategists. With the DOW hitting new highs at 14,263 (and forgetting about the 2001 NASDAQ 5000 high which is still 2000 points...
by Raynovich Rod | Mar 1, 2013 | Macro
High Beta Technicals-Resiliency Rules With NAZ, Dow and S&P up about 0.24%. Lots of volatility today with MO stocks as BIG money trolls along: CLDX ($10.34) up 54.8% YTD, $640M Market Cap. IBB ($149) ETF up 1% at new highs should hit $150. INFI ($43.95) up 6.5%...
by Raynovich Rod | Feb 15, 2013 | BIOgraph, Macro
The Stock Market Realty Shows In case you missed it stocks lately are being driven by hedge funds and celebrity billionaires who tout their positions. The Icahn vs Ackman drama is the latest high profile realty show featured mainly by CNBC-TV. Biotechnology stocks...
